Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company’s lead ...

Cyclo Therapeutics (CYTH) down -23.10% to $0.97 premarket. Rafael Holdings (RFL) will issue shares of its Class B common ...

The leaked but unconfirmed images, which you can see embedded below, are renders that VGC confirms with a source that look like what Nintendo is doing for the console, and there are at least a ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Short interest in Cyclo Therapeutics Inc (NASDAQ:CYTH) increased during the last reporting period, rising from 199.99K to 254.12K. This put 1.03% of the company's publicly available shares short.

Cyclo Therapeutics, Inc. (NASDAQ:CYTH), a biopharmaceutical company specializing in biological products, has entered into a financial agreement with Rafael Holdings, Inc.,... ByInvesting.com ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...